Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Evolocumab · 1 trial · 1 indication
Indication for intubation determined individually for each patient and clinical status
| Arm | Type | Description |
|---|---|---|
| PCSK9 inhibitor (evolocumab) | EXPERIMENTAL | 140 mg of evolocumab as a single subcutaneous injection and standard of care accordance to the latest recommendations |
| Usual Care | PLACEBO_COMPARATOR | 1 ml of 0,9% saline solution as a single subcutaneous injection. Patients will be treated in accordance to the latest recommendations on caring for patients infected with SARS-CoV-2. |
| Name | Type | Description |
|---|---|---|
| Evolocumab | DRUG | A single subcutaneous administration of 140 mg evolocumab |
| Saline solution | DRUG | A single subcutaneous injection of 1ml of 0,9% saline solution |
Inclusion Criteria: 1. Written informed consent for participation in the study 2. Male and female age 18 or more at the time of signing the informed consent 3. SARS-CoV-2 infection confirmed by Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) 4. COVID-19 pneumonia with a typical r...
Top 20 of 28 competitors
Evolocumab is a small molecule being studied for the treatment of Sars-CoV-2 Infection. It is currently in Phase 3 clinical development. The drug is being investigated for its impact on clinical outcomes in patients during the inflammatory stage of COVID-19.
Evolocumab is being developed by Collegium Pharmaceutical, Inc., which is publicly traded under the ticker symbol COLL. The company is conducting clinical research on this drug for the treatment of Sars-CoV-2 Infection.
Evolocumab is in Phase 3 clinical development. It is an investigational drug being studied for Sars-CoV-2 Infection. The Phase 3 trial has been completed, and the drug is not yet approved for any use.
Evolocumab has one completed Phase 3 clinical trial with the identifier NCT04941105. This trial, titled 'Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19', enrolled 60 participants in Poland and was placebo-controlled and double-blind.
Evolocumab is being studied for its impact on PCSK9 inhibition, as indicated by the clinical trial title. The trial specifically evaluates the effect of PCSK9 inhibition on clinical outcomes in COVID-19 patients, suggesting the drug's mechanism involves targeting the PCSK9 pathway.